The News Review:

- First clinical trial firm on Polish bourse?
- Business Leader Media to Host Business Leader Breakfast August 21
- Vicus Therapeutics to Present at the 234th American Chemical Society…
- HIV’s punch brings on dementia

First clinical trial firm on Polish bourse?
Polish Market – Aug 16, 2007
At this early stage of preparations no more information is available. According to the PMR report “Clinical trials in Poland 2007” the Polish clinical research market will grow by 10-12% in 2007 to a value in excess of PLN 600m (€). Adam Kruszewski vice-president of Kiecana Clinical Research believes that the Polish clinical trials market is potentially the most interesting in the world but the main obstacle to its development is excessive bureaucracy chiefly the long time it takes to register a trial. It takes about 80 days in Poland (it should take no longer than 60 days by law) compared to about 30 days in the Czech Republic or Slovakia and this is why these countries are often preferred to Poland. In the opinion of Mr Kruszewski if the trial registration period was halved the value of the Polish clinical research market would double. Mr Kruszewski does not agree that the Polish clinical trial market is becoming more saturated than other Central and Eastern European (CEE) markets such as Romania or Ukraine. In his opinion patients in Poland still have very poor access to innovative therapies and doctors are still keen to participate in trials… Mr Kruszewski does not agree that the Polish clinical trial market is becoming more saturated than other Central and Eastern European (CEE) markets such as Romania or Ukraine. In his opinion patients in Poland still have very poor access to innovative therapies and doctors are still keen to participate in trials. What is more boosting the clinical research market in Poland would help to solve the problem of low wages in Polish health care recently the cause of strikes Mr Kruszewski believes.

Business Leader Media to Host Business Leader Breakfast August 21
PR.com – PR.com (press release) – Aug 16, 2007
Albert Siemens CE and chairman of the board of directors for Family Health International (FHI) joined the organization in 1983 as director of clinical trials eventually serving as vice president of research where he was responsible for FHI’s multi-national clinical studies. In 1986 Siemens was instrumental in the formation of Clinical Research International (CRI) an FHI affiliate that provided clinical research services to medical companies. He served as its president until it was sold to ClinTrials Research Inc. He served as executive vice president of ClinTrials from 1991 to 1997 and rejoined FHI in 1998 as CE. The event will be held from 7:30 a.

Vicus Therapeutics to Present at the 234th American Chemical Society…
Genetic Engineering News – Genetic Engineering News (press release) – Aug 16, 2007
In addition he will review recent changesby the Drug Controller General of India (DCGI the Indian FDA-regulatoryequivalent) Indian clinical research infrastructure and the acceptance ofIndian data by the U. Food & Drug Administration (FDA) that is currentlydriving the explosive growth of clinical research in India. Maki’spresentation is scheduled for 4:25 p.

HIV’s punch brings on dementia
The Australian – Aug 16, 2007
In people the dementia triggered by the virus HIV-associated dementia (HAD) slows thinking memory and even movement. Perversely although highly active anti-retroviral therapy (HAART) helps HIV-infected people live longer and with less severe dementia the prevalence of HAD has not declined. Statistics from the National Centre in HIV Epidemiology and Clinical Research (NCHECR) at the University of NSW in Sydney reveal that almost 9800 Australians have HIV-AIDS. According to Bruce Brew — head of neurology at St Vincent’s Hospital in Sydney — roughly 20 per cent of people with AIDS will develop HAD. Surprisingly many will remain otherwise quite well. "This explains what’s going on" Professor Brew said. "It provides a mechanism for the impairment.